|
| Pathway | FDR |
Number of genes in pathway | Number of common genes |
|
| Agranulocyte Adhesion and Diapedesis | FDR = | (ng = 173) | (nc = 62) |
| Atherosclerosis Signaling | FDR = | (ng = 119) | (nc = 44) |
| Granulocyte Adhesion and Diapedesis | FDR = | (ng = 163) | (nc = 53) |
| LXR/RXR Activation | FDR = | (ng = 121) | (nc = 42) |
| Inhibition of Matrix Metalloproteases | FDR = | (ng = 38) | (nc = 19) |
| Hepatic Fibrosis/Hepatic Stellate Cell Activation | FDR = | (ng = 137) | (nc = 44) |
| Acute Phase Response Signaling | FDR = | (ng = 167) | (nc = 49) |
| ILK Signaling | FDR = | (ng = 181) | (nc = 52) |
| Ethanol Degradation II | FDR = | (ng = 30) | (nc = 15) |
| Intrinsic Prothrombin Activation Pathway | FDR = | (ng = 28) | (nc = 14) |
| Coagulation System | FDR = | (ng = 35) | (nc = 16) |
| Extrinsic Prothrombin Activation Pathway | FDR = | (ng = 16) | (nc = 10) |
| Noradrenaline and Adrenaline Degradation | FDR = | (ng = 32) | (nc = 15) |
| Bladder Cancer Signaling | FDR = | (ng = 86) | (nc = 29) |
| Axonal Guidance Signaling | FDR = | (ng = 421) | (nc = 98) |
| Ethanol Degradation IV | FDR = | (ng = 17) | (nc = 10) |
| Colorectal Cancer Metastasis Signaling | FDR = | (ng = 232) | (nc = 60) |
| Wnt/_-catenin Signaling | FDR = | (ng = 167) | (nc = 46) |
| Cardiac_-adrenergic Signaling | FDR = | (ng = 132) | (nc = 38) |
| Protein Kinase A Signaling | FDR = | (ng = 365) | (nc = 84) |
| LPS/IL-1 Mediated Inhibition of RXR Function | FDR = | (ng = 210) | (nc = 52) |
| EIF2 Signaling | FDR = | (ng = 171) | (nc = 11) |
| Epithelial Adherens Junction Signaling | FDR = | (ng = 144) | (nc = 38) |
| HIF1_Signaling | FDR = | (ng = 100) | (nc = 29) |
| Oxidative Ethanol Degradation III | FDR = 3 | (ng = 15) | (nc = 8) |
| Retinoate Biosynthesis I | FDR = | (ng = 29) | (nc = 12) |
| Factors Promoting Cardiogenesis in Vertebrates | FDR = | (ng = 87) | (nc = 26) |
| GADD45 Signaling | FDR = | (ng = 19) | (nc = 9) |
| Mitotic Roles of Polo-Like Kinase | FDR = | (ng = 62) | (nc = 20) |
| TR/RXR Activation | FDR = | (ng = 85) | (nc = 25) |
| Aryl Hydrocarbon Receptor Signaling | FDR = | (ng = 133) | (nc = 35) |
| Role of Osteoblasts, Osteoclasts | FDR = | (ng = 214) | (nc = 50) |
| Estrogen-mediated S-phase Entry | FDR = | (ng = 24) | (nc = 10) |
| Calcium Signaling | FDR = | (ng = 168) | (nc = 41) |
| Estrogen Receptor Signaling | FDR = | (ng = 126) | (nc = 8) |
| Triacylglycerol Biosynthesis | FDR = | (ng = 33) | (nc = 12) |
| Mitochondrial Dysfunction | FDR = | (ng = 139) | (nc = 10) |
| Thyroid Cancer Signaling | FDR = | (ng = 40) | (nc = 14) |
| Human Embryonic Stem Cell Pluripotency | FDR = | (ng = 132) | (nc = 34) |
| FXR/RXR Activation | FDR = | (ng = 82) | (nc = 22) |
| Glycogen Degradation II | FDR = | (ng = 9) | (nc = 5) |
| Putrescine Degradation III | FDR = | (ng = 16) | (nc = 7) |
| Tryptophan Degradation X | FDR = | (ng = 16) | (nc = 7) |
| Dopamine Degradation | FDR = | (ng = 21) | (nc = 8) |
| Glioma Invasiveness Signaling | FDR = | (ng = 57) | (nc = 17) |
| Actin Cytoskeleton Signaling | FDR = | (ng = 210) | (nc = 47) |
| NAD biosynthesis II (from tryptophan) | FDR = | (ng = 13) | (nc = 6) |
| Fatty Acid_-oxidation | FDR = | (ng = 13) | (nc = 6) |
|
